ASCOcancer

9.2K subscribers

371 videos

As the leading medical society representing doctors who care for people with cancer, the American Society of Clinical Oncology (ASCO) is committed to conquer...

Latest Videos

2026 Oncology Coding Updates

2026 Physician Fee Schedule Final Rule

ASCO Guidelines Assistant

PARP Inhibitor + SOC Improves rPFS in HRR-Altered mCSPC in AMPLITUDE Trial

Maintenance Lurbinectedin + Atezolizumab Improves Survival Outcomes in ES-SCLC in IMforte Trial

Combination Atezolizumab + FOLFOX Improves DFS in Stage III dMMR Colon Cancer in ATOMIC Trial

Durvalumab + FLOT Yields Significantly Improved EFS in GastricGEJ Cancer in MATTERHORN Trial

ctDNA-Guided Camizestrant + CDK46i Extends PFS in ESR1-Mutated, HR+HER2– Advanced Breast Cancer

Rusfertide Reduces Phlebotomy Burden, Improves Disease-Related Symptoms in Polycythemia Vera

Nivolumab + CRT Improves DFS in High-Risk Locally Advanced HNSCC in NIVOPOSTOP Trial

Vepdegestrant Improves PFS vs Fulvestrant in ESR1-Mutated, ER+HER2– Advanced Breast Cancer

Coding for Health-Related Social Needs and Social Determinants of Health

2025 Medicare Physician Fee Schedule and Hospital Outpatient Final Rule Updates

2025 Oncology Coding Updates

2025 Physician Fee Schedule Proposed Rule and the Impact on Oncology

First-Line NivolumabIpilimumab Improves Survival in Unresectable Hepatocellular Carcinoma

Nivo+GemCis Is Durable, Improves Survival in Patients With Lymph Node–Only mUC

Neoadjuvant Nivolumab + Ipilimumab Could Be New SOC in Stage III Melanoma

CROSS Inferior to FLOT in Patients With Esophageal Adenocarcinoma

Telehealth Equally Effective as In-Person Palliative Care in Maintaining QOL in Advanced Lung Cancer

Osimertinib Improves PFS in EGFR-Mutant, Unresectable, Stage III NSCLC

Consolidation Durvalumab Could Be New SOC in Limited-Stage SCLC

Adagrasib Improves PFS in Patients With KRASG12C-Mutated NSCLC

Amivantamab + Lazertinib Administration Method May Affect Outcomes in Advanced NSCLC

Dr. Angela DeMichele on Why You Should Attend Our Flagship Best of ASCO Meeting

Dr. Melvin Chua Invites You to Register for #ASCOBT24

Save the Date for #ASCOBT24 August 8-10, 2024, in Yokohama, Japan

Dr. Melvin Chua on Why You Can't Miss #ASCOBT24

Systemic Treatment of Patients with Metastatic Breast Cancer ASCO Resource-Stratified Guideline

Regional Affiliate Program